The Endocrine Society Recommends Against Changes In Blood Sugar Control Goals In Response To Study On A1C Levels And Mortality Published In Lancet
A study published this week in Lancet suggests that low A1C levels may be just as dangerous as high A1C levels in diabetes patients with respect to mortality and cardiovascular outcomes. Upon review of the study, The Endocrine Society released a statement recommending against any wholesale change in glycemic goals and strongly encourages patients to discuss these issues with their diabetes-care providers. Measurements of A1C show the percentage of hemoglobin (the main component of red blood cells) in the blood that is glycated, i.e., has glucose attached to it. The A1C blood test is currently one of the mainstays of diabetes management because it reflects the average blood sugar levels for the previous two to three months.
Increasing rates of obese and overweight children in the United States may be contributing to a later onset of puberty in boys, say researchers at the University of Michigan. In a new study published in the February issue of the Archives of Pediatrics and Adolescent Medicine, researchers show that a higher body mass index during early and mid-childhood for boys is associated with later onset of puberty. This is one of the first longitudinal studies in the U.S. to examine the association between weight status and timing of puberty in boys. "We found that increased body fatness is associated with a later onset of puberty in boys, the opposite of what we have seen in girls, as heavier girls tend to develop earlier, rather than later.
Fat tissue in women with Polycystic Ovary Syndrome produces an inadequate amount of the hormone that regulates how fats and glucose are processed, promoting increased insulin resistance and inflammation, glucose intolerance, and greater risk of diabetes and heart disease, according to a study conducted at the Center for Androgen-Related Research and Discovery at Cedars-Sinai Medical Center. Polycystic Ovary Syndrome, or PCOS, is the most common hormonal disorder of women of childbearing age, affecting approximately 10 percent of women. It is the most common cause of infertility, and an important risk factor for early diabetes in women.
Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from The University of Texas M. D. Anderson Cancer Center report in Clinical Cancer Research. The M. D. Anderson research, led by Khandan Keyomarsi, Ph.D., professor in M. D. Anderson's Department of Experimental Radiation Oncology and the Hubert L. and Olive Stringer Professor in Medical Oncology, found evidence that women whose cancers express the LMW-E are more likely to develop resistance to letrozole. However, their research also showed that treating breast cancer cells with a cyclin-dependent kinase 2 (CDK2) inhibitor can reverse letrozole resistance.
American Association Of Clinical Endocrinologists Applauds First Lady Michelle Obama's Crusade Against Obesity
The American Association of Clinical Endocrinologists (AACE) welcomes and applauds the effort of First Lady Michelle Obama, who announced a new campaign to combat childhood obesity today. AACE and the American College of Endocrinology (ACE), have initiated a number of programs and activities that will compliment her efforts. "First Lady Obama's actions will also help to increase public awareness about the College's efforts, " AACE President Dr. Jeffrey R. Garber said. ACE is the scientific arm of the American Association of Clinical Endocrinologists (AACE), whose members specialize in endocrinology, diabetes, and metabolism. An integral component in the ACE effort to combat obesity centers on the Power of Prevention®
Shenogen And Chemizon Announce Drug Discovery Collaboration Focused On Oncology And Endocrine Disorders
Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. (KOSDAQ: 0101070) today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor. "We are very pleased to enter into this collaboration with Chemizon whose experienced management team has a track record of success in creating promising drug candidates, " said Dr. Jin Li, President of Shenogen Pharma Group. "This collaboration underscores our commitment towards creating orally administered, small molecule modulators of the non-classical Estrogen Receptor pathway that target indications including metastatic breast cancer and osteoporosis.